XML 59 R51.htm IDEA: XBRL DOCUMENT v3.23.1
LICENSE AGREEMENTS AND DISCOVERY COLLABORATIONS (Details)
$ in Thousands
1 Months Ended 3 Months Ended
May 03, 2023
USD ($)
Oct. 26, 2020
USD ($)
Jul. 22, 2020
USD ($)
Jul. 31, 2020
USD ($)
Mar. 31, 2023
USD ($)
item
Mar. 31, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development         $ 70,933 $ 53,428
License agreements | item         2  
Agreement funded based on Developmental criteria            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount         $ 500  
Agreement for development of Aumolertinib            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Upfront payment amount     $ 25,000 $ 20,000    
Duration of royalty period     11 years 10 years    
Termination notice period     180 days      
Agreement for development of Aumolertinib | Agreement funded based on Developmental and Regulatory criteria            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount     $ 55,000      
Agreement for development of Aumolertinib | Agreement funded based on Sales criteria            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount     350,000      
Agreement for development of Aumolertinib | Maximum | Agreement funded based on Developmental and Regulatory criteria            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount       $ 40,000    
Agreement for development of Aumolertinib | Maximum | Agreement funded based on Sales criteria            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount     420,000 $ 250,000    
Agreement for development of Sugemalimab and Eq176 | Maximum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount   $ 107,500        
Agreement for development of Sugemalimab and Eq176 | Maximum | Agreement funded based on Sales criteria            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount   565,000        
Agreement for development of Sugemalimab            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Upfront payment amount   150,000        
Agreement for development of Sugemalimab | Agreement funded based on Developmental and Regulatory criteria            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Upfront payment amount   $ 10,000        
Agreement for development of Sugemalimab | Maximum | Agreement funded based on Developmental and Regulatory criteria            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Upfront payment amount     $ 90,000      
Agreement for development of Eq176            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Duration of royalty period   11 years        
Agreement for development of Eq176 | Maximum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount   $ 75,000        
Agreement for development of Eq176 | Maximum | Agreement funded based on Sales criteria            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount   $ 405,000        
License Agreements            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development         5,000  
Non-creditable payment         7,500  
License Agreements | Maximum | Agreement funded based on Developmental criteria            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount         32,500  
License Agreements | Maximum | Agreement funded based on Regulatory criteria            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount         73,000  
License Agreements | Maximum | Agreement funded based on Sales criteria            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount         225,000  
Discovery collaborative agreements            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development         $ 7,600 $ 8,800
Lynk License Agreement | Maximum | Agreement funded based on Developmental criteria | Subsequent Event [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount $ 13,000          
Lynk License Agreement | Maximum | Agreement funded based on Regulatory criteria | Subsequent Event [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount 39,000          
Lynk License Agreement | Maximum | Agreement funded based on Sales criteria | Subsequent Event [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment amount $ 120,000